Lymphoma risk in autoimmune diseases with multiple medication use: analysis from the LIFE Study

Area of Science:

• Immunology
• Oncology
• Rheumatology

Background:

• Autoimmune diseases (AIDs) are linked to higher lymphoma incidence.
• Recent data on lymphoma risk in AIDs, especially with new treatments, is scarce.
• The impact of multiple medications on lymphoma risk in AIDs requires investigation.

Purpose of the Study:

• To assess lymphoma risk in patients with autoimmune diseases.
• To investigate the influence of immunosuppressive/immunomodulatory agents on this risk.
• To evaluate the effect of polypharmacy on lymphoma development in AIDs.

Main Methods:

• Utilized the LIFE Study database (2014-2023) with healthcare claims data from Japan.
• Analyzed data from 2,229,423 individuals, including 211,592 with AIDs.
• Conducted a large-scale cohort study to determine hazard ratios (HR) for lymphoma.

Main Results:

• Patients with AIDs had a significantly higher lymphoma incidence (HR 1.9).
• Lymphoma risk was elevated in 14 out of 23 AIDs, notably Takayasu arteritis (HR 6.6) and adult-onset Still's disease (HR 4.7).
• Use of calcineurin inhibitors, iguratimod, methotrexate, and multiple medications (≥2, HR 2.7) increased lymphoma risk.

Conclusions:

• Autoimmune disease patients face a heightened risk of lymphoma.
• The use of multiple immunosuppressants/immunomodulators significantly amplifies this risk.
• Close monitoring of AIDs patients, especially those on combination therapy, is crucial for early lymphoma detection.